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Abstract 
Uracil is a non-canonical base in DNA that can arise through misincorporation of 
dUMP instead of dTMP during replication or from cytosine deamination. Uracil in DNA can 
be removed by the four different DNA glycosylases UNG, SMUG1, TDG or MBD4 as the 
first step in base excision repair. These glycosylases have different catalytic efficiencies, 
different substrate preferences and different expression patterns. We wanted to elucidate the 
contribution of the different DNA glycosylases in removal of uracil, using protein extracts 
from mouse brain, small intestine, kidney, liver, lung and muscle. Importantly, UNG
+/+
 and 
UNG
-/- 
mice were available for these studies. Furthermore, we used the UNG-specific 
inhibitor Ugi to inhibit UNG-activity and an anti-SMUG1 antibody PSM1 to inhibit SMUG1 
activity. In addition, we used a combination of Ugi and PSM1 to inhibit both UNG and 
SMUG1 activities. To investigate the contribution of the DNA glycosylases in different 
sequence contexts, we used uracil-containing DNA substrates with uracil in a U:G mismatch, 
a U:A pair, or in single stranded DNA. We found that UNG was by far the most important 
DNA glycosylase removing uracil from U:A pairs and from single-stranded DNA, even in 
extracts from non-proliferative tissues such as brain and muscle. However, we found that 
UNG and SMUG1 are almost equally active in removal of uracil from a U:G context in 
extracts from non-proliferative tissues. In contrast, SMUG1 contributed very little to the 
removal of uracil from small intestines, which presumably contain a higher fraction of rapidly 
dividing cells. Furthermore, we detected essentially no residual uracil-DNA glycosylase 
activity when both UNG and SMUG1 were specifically inhibited, indicating that TDG and 
MBD4 do not contribute measurable activity in any of the organs investigated under the 
conditions used here. Possibly these DNA glycosylases can only contribute in sequence 
patterns that have not been investigated here. We also carried out a preliminary study on the 
possible correlation between genomic uracil contents (measured by mass spectrometry) and 
uracil excision activities, but failed to observe a significant positive correlation or inverse 
correlation. In conclusion, UNG is the dominant uracil-DNA glycosylase in proliferating 
tissues in removal of uracil from a U:G context, whereas in non-proliferating tissues the 
contribution of UNG and SMUG1 is essentially similar. Furthermore, UNG is the only 
glycosylase removing uracil from U:A and single stranded DNA contexts.  
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1. Introduction 
Eukaryotic cells undergo strict DNA replication and repair processes to ensure proper 
transmission of genetic material from a mother to a daughter cell. DNA lesions may arise 
endogenously from e.g. oxidation, hydrolysis, and deamination, and exogenous threats 
emerge from sources like ionizing radiation and various chemical agents. If not repaired, these 
lesions may lead to mutagenesis, apoptosis, cancer, and neurological disorders (1). DNA 
repair pathways have evolved in all organisms that repair most DNA lesions. 
Nucleobases are sub-categorized into purines and pyrimidines (2). The purine bases 
are adenine (Ade) and guanine (Gua) and the pyrimidines are thymine (Thy) and cytosine 
(Cyt). In the Watson-crick model, pyrimidines base-pair with purines by hydrogen-bonding, 
with Ade opposite to Thy (A:T) and Gua opposite to Cyt (G:C). Uracil (Ura) is a canonical 
RNA base which, instead of Thy, base pairs with Ade under normal conditions. Ura may also 
be found in very small amounts in DNA as a result of 2’-deoxyuridine-5’-triphosphate 
(dUTP) misincorporation during replication and Cyt deamination. Misincorporation of 2’-
deoxyuridine-5’-triphosphate (dUTP) instead of 2’-deoxythymidine-5’-triphosphate (dTTP) 
leads to U:A pairing while Cyt deamination results in a more mutagenic U:G pair (3). 
Genomic Ura, regardless of the source, is recognized by uracil-DNA-glycosylases (UDGs), 
which recognize and excise the lesion to begin repair by the base excision repair (BER) 
pathway (4); however, studies reveal that genomic uracilation, in selected regions, is also 
crucial for antibody diversification. 
1.1. Sources of uracil in DNA 
1.1.1. dUTP misincorporation during DNA synthesis 
In a mammalian cell, dUTP is a natural intermediate in the pyrimidine metabolism 
pathway (5). dUTP emerges from nucleoside diphosphate kinase (NDPK)-dependent 
phosphorylation of 2’-deoxyuridine-5’-diphosphate (dUDP) following  ribonucleoside 
diphosphate reductase (rNDPase) activity and by random phosphorylation of 2’-deoxyuridine-
5’-monophosphate (dUMP), a crucial precursor of 2’-deoxythymidine-5’monophosphate 
(dTMP). In turn, dUMP stems either from thymidine kinase dependent phosphorylation of 
deoxyuridine (dU) or by 2’-deoxycytidine-5’monophosphate (dCMP) deamination (3). 
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However, dUTP levels are regulated by 2’-deoxyuridine-5’-triphosphate nucleotide hydrolase 
(dUTPase) by hydrolyzing dUTP to dUMP (6).  
Due to the structural similarity of dUTP and 2’-deoxythymidine-5’triphosphate 
(dTTP), most replicative polymerases fail to differentiate between the two and therefore 
aberrantly incorporate dUTP with a similar efficiency to dTTP during DNA synthesis (1). The 
frequency of misincorporation in a growing chain in human DNA has estimated to be about 
one dUTP residue per 10
4
 dTTPs per cell per day (7). The degree of dUMP mis-incorporation 
into the growing DNA chain depends on the relative quantities of dTTP and dUTP, the 
respective concentrations of which vary between 30-37 µM to 0.2 µM (8). Therefore, the 
intracellular concentration of dUTP is as low as 1% of that of dTTP (9). Studies support that 
most of the genomic uracil is incorporated during replication: about 3600 uracil per genome 
in proliferating cells (embryonic fibroblasts) and about 900-1400 Ura residues per genome in 
non-dividing cells (hepatocytes) (10). 
dUTP misincorporation leads to a U:A base-pair which is not inherently mutagenic 
because U:A replicates to T:A (1). Genomic uracil-induced cytotoxicity might occur when 
misincorporation occurs in promoter regions altering the binding of transcription factors and 
in turn compromises transcription (11). It may also occur by abasic site formation resulting 
from glycosylase activity leading to topoisomerase halt and frequent single stranded breaks all 
over the genome (12).  
The dUTP misincorporation rate is increased with decreased dUTPase activity, 
cytostatic drug treatment, folate deficiency, and reduced thymidylate synthase (TS) activity 
(13). Folate is an important cofactor for dTMP generation with co-substrate substrate N5, 
N10-methylene-tetrahydrofolate (MTHF) and aids the conversion of dUMP to dTMP and 
dihydrofolate (DHF) by the catalyzing action of TS. During thymidylate biosynthesis, TS uses 
MTHF as a methyl donor to dUMP and dihydrofolate reductase (DHFR) enhances MTHF 
regeneration in every step of continued dTMP synthesis (3). TS activity may be inhibited by 
the folate antagonist methotrexate, and/or folic acid deficiency and leads to an increase in the 
dUMP level in cells (14). Thus, this pathway has been the target of several anticancer drugs 
like 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUrd), and pemetrexed. 
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1.1.2. Cytosine deamination 
Cytosine deamination is a major source of uracil in DNA and may arise in several 
ways as discussed below. 
1.1.2.1. Spontaneous deamination 
Under normal physiological conditions, cytosine deamination occurs in two different 
pathways (15). As shown in Figure 1-1, the direct hydrolytic deamination pathway follows an 
intramolecular process of nucleophilic attack of a hydroxyl ion (OH
-
) on an unstable 
exocyclic amino group at the C4 position of the base. This reaction releases ammonia to give 
rise to an intermediate product- uridine hydrate (6-hydroxy-5,6-dihydro-uridine) that 
subsequently dehydrates to uridine (I->III->IV). The addition-elimination pathway is 
comprised of a hydroxylic attack at the C5,C6 double bond of the protonated base to form 
cytidine hydrate that eventually gives rise to uracil in the double helix (II->V->IV).  
 
Figure 1-1: Spontaneous chemical deamination of dC. (A.) Direct hydrolytic deamination 
via alkali-catalyzed hydrolysis or (B.) water attack on the protonated base (modified from 
Shapiro (15))    
These reactions depend on various parameters like temperature, pH, and the state of 
DNA: single or double stranded (16). Acidic pH (within the range of 1-3) accelerates the 
deamination rate by converting the substrate to a more protonated form, whereas, alkalic pH 
converts the substrate into a less anionic form by substituting an effective nucleophilic agent- 
OH
-
. In an acidic condition of pH 3 at 25
o
C, one out of every 10,000 protonated 
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deoxycytidine residues exists as hydrates. In order to extrapolate the cytosine deamination 
rate, Lindahl et al. conducted an experiment by increasing the temperature range. At 100
o
C 
and at neutral pH, they measured one uracil per 5000 cytosine residues (16). Under normal 
biological conditions, double-stranded DNA is less prone (<1%) to undergo deamination than 
single-stranded DNA. Based on the results of Frederico et al., an estimated 70-200 uracil 
residues could be formed per cell per day provided 0.1% of the genome becomes single 
stranded at any time point (17). These mutagenic deaminations lead to U:G mispairs and 
result in transition mutations from G:C to A:T, if tolerated until the next round of replication 
(18).  
1.1.2.2. Non-enzymatic deamination 
Several chemicals have been shown to increase the cytosine deamination rate. Nitrous 
anhydride (N2O3) induces deamination upon oxidation of nitric oxide (NO
.
) that originates 
from arginine (Arg) oxidation (19). This intermediate works on both ss- and ds-DNA with 
similar efficiency and is widely produced in vivo in response to various types of chronic 
inflammations (20). Sodium bisulphite also causes to cytosine deamination and has been 
found in many food items (3). 
Apart from chemicals, cytosine deamination may arise from different types of 
radiation. The major source is UV irradiation, which leads to the formation of cyclobutane 
pyrimidine dimers (CPDs) and 6-4 photoproducts (6-4-PP). CPDs are the one of the important 
mutagenic lesions in mammalian cells (21) and they are generated at a much higher rate, 
about 5-10 fold higher frequency, than the 6-4 photoproducts (22,23). Cytosine involved in a 
CPD undergoes higher rate of deamination (24-26). Uracil lesions produced in this way are 
difficult to alter as most mammals lack photolyase to reverse the CPD crosslink and rely only 
on the nucleotide excision pathway (NER) for repair (1). 
1.1.2.3. Enzymatic deamination of cytosine 
There are two main types of enzymes responsible for deamination: most importantly 
deoxycytidine deaminases (27) and the less potent cytosine-5-methyltransferase (28). The 
latter is mainly responsible for DNA modifications during epigenetic gene silencing by 
converting CpG cytosine to 5-methylcytosine (5-mC). Methyltransferases transfer a methyl 
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group to cytosine utilizing S-adenosylmethionine (SAM) as a methyl donor. 
Methyltransferases have been shown to deaminate Cyt when SAM concentration is low (29). 
In higher vertebrates, the apolipoprotein B mRNA editing polypeptide (APOBEC) 
family of proteins has been shown to deaminate cytosine, among which AID plays an 
important role in adaptive immunity (30). APOBEC2, APOBEC4, and AID are present in 
both humans and mice (reviewed in (3)). 
AID deaminates cytosine in targeted immunoglobin gene loci to activate antibody 
diversification through class switch recombination (CSR) and somatic hypermutation (SHM) 
(31). This enzyme is usually active in B-cell germinal centers (BGCs) (32). Apart from 
adaptive immunity, AID may has a role in DNA demethylation during reprogramming of 
pluripotent stem cells (33) and in primordial germ cells (PGCs) (34). Cytosine deamination by 
AID occurs in 2-7kbp long hot-spots of DNA using the following motif: WRCY (W=A/T, 
R=A/G, C/Y=T/A). It has been found that AID deaminates cytosine in about 25% of 
expressed genes in mouse BGC thus correlating its importance as a source or uracil in DNA 
(32). 
1.2. Consequences of Uracil in DNA 
Eukaryotic organisms respond to DNA damage in a variety of ways. They eradicate or 
tolerate the damage or respond by inducing apoptosis. 
1.2.1. DNA mutagenicity 
U:A base-pairing in DNA originates from dUTP misincorporation, which is not 
directly  mutagenic but can give rise to mutagenic abasic sites (10). Cytosine deamination is 
more efficient on deoxynucleosides (dNs), less in single stranded DNA (ss-DNA), and the 
least efficient in double stranded DNA (35). Uracil occurring from in this process results in 
U:G mispair that produces C>T transition mutations after one cycle of replication resulting in 
a change in the original sequence (Figure 1-2). Uracil N’-glycosylase (UNG) has a high range 
of selectivity for ss-DNA substrate over double stranded, and U:G over U:A (36). Likewise, 
AP site formation in DNA is cytotoxic because it irreversibly traps topoisomerase I, an 
enzyme responsible for unwinding and over winding of DNA during replication which halts 
the replication and transcription processes (2,37). 
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Figure 1-2: Consequences of misincorporation of dUMP and cytosine deamination that 
are not repaired. U:A base pair in DNA results from incorporation of dUTP instead of 
dUMP by polymerases. U:G mispair occur after deamination of Cyt to Ura, resulting in C:G 
to T:A mutation transition after second round of replication (modified from Sousa 2007) 
An estimated 200 Cyt residues are spontaneously deaminated per mammalian diploid 
genome per day (18), but recent studies show the global genomic uracil content in the genome 
of UNG-active cell to be about 400-600 residues with a 10 fold increase in UNG-deficient 
cells (38). 
1.2.2. Repair of genomic uracil 
Genomic uracil is repaired by the base excision repair (BER) pathway (39).  BER is 
typically responsible for repair of a large number of small base lesions that do not distort the 
helical structure of DNA (2,40,41). These types of base lesions are the result of deamination, 
misincorporation, base methylation, oxidative base damage, and DNA replication faults that 
occur spontaneously or by environmentally induced factors. BER occurs both in the nucleus 
and mitochondria that frequently use the isoform of glycosylases originating from splicing of 
the same gene. It is one of the important pathways in relation to cancer, neurodegeneration, 
and aging (42). 
The basic steps of BER are damage recognition, base removal, strand incision, end 
trimming/ processing, repair synthesis by nucleotide insertion, and ligation (43). These 
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“common steps” may differ in vivo depending on the recruitment of different glycosylases as 
well as the physiological state of the cell. The common mechanism followed by all DNA 
glycosylases is to flip the faulty base out of the helix into the substrate recognition site of the 
enzyme so as to create an apurinic (AP)- site by cleaving N’-glycosyl bond between C1-
carbon of 2’-deoxyribose and the inappropriate/ damaged base. The second step is carried 
forward by AP endonuclease 1 (APE1), which recognizes the abasic site, and cut the 
phosphodiester bond on the 5’end of AP-site, forming a free 3’-OH and 5’-deoxyribose-
phosphate (5’-dRP) moiety. This 3’-OH serves as the substrate for new strand synthesis in 
case of monofunctional glycosylases. Bifunctional glycosylases carry an additional AP-lyase 
activity site that cleaves the phosphodiester bond on the 3’ end of the AP site producing a 3’-
dRP (unsaturated hydroxyaldehyde) and a 5’-P end. In this case 5’-end processing is required 
as it is considered a polymerase blocking lesion and also DNA ligases need free 5’-phosphate 
and 3’-OH ends on either sides to seal the nick. The end-cleaning action is completed by 
APE1 or polynucleotide kinase 3’-phosphatase (PNPK) prior to base insertion. The 
downstream step recruits DNA polymerase β (POL-β) which adds one nucleotide and 
removes the dRP from the DNA chain. Polymerization takes place following recruitment 
different enzymes or complexes of enzymes: short patch BER (SP-BER) that replaces a single 
nucleotide and long patch BER (LP-BER) replaces 3-12 nucleotides. As shown in Figure 1-3, 
in SP-BER, which is also known as “single-nucleotide” BER, gap-filling is carried out by Pol-
β which inserts a single base and removes the dRP alongside. The nick is sealed by DNA 
ligase I (LIG1) in complex with scaffold protein X-ray repair cross-complementing protein 1 
(XRCC1). LP-BER replaces several nucleotides by the aid of replication enzymes. Pol ∂/ε or 
Pol-β synthesizes the new strand in complex with proliferating cell nuclear antigen (PCNA) 
and replication factor C (RCF). The strand produced in this way is digested by flap 
endonuclease (FEN1); dRP is removed as a part of the flap in LP-BER. To complete the 
repair process, the nick is ligated by LIG1 (44,45) (reviewed in (41)). 
The factors that decide whether SP-BER or LP-BER takes place are still unelucidated. 
One explanation for the switch to LP-BER is the presence of 5’-dRP which restricts the 
activity of Pol-β lyase (46). Nevertheless, bifunctional glycosylases tend to undergo SP-BER 
while monofunctional glycosylases exhibit no preference (47). However, SP-BER is a 
dominant pathway in both proliferating and non-proliferating cells, while LP-BER has mainly 
been found in proliferating cells. Other factors include proteins involved in postreplicative 
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BER, such as UNG2 and NEIL1 (48) which are found in highest level in S-phase of a 
proliferating cell (49). 
 
Figure 1-3: Schematic overview of SP- and LP-BER pathways. UNG recognizes and 
excises Ura and APE1 cleaves the DNA at the resulting AP site. In short patch BER, Pol-β 
replaces excised nucleotide and LIG1 ligates the strand. In long patch BER, Pol ∂/€ insert the 
rest of the nucleotides, the flap is removed by FEN1, and DNA is ligated by LIG1 (modified 
from Sousa, 2007). 
1.2.2.1. Different types of Uracil DNA glycosylases 
The human genome encodes for four different uracil DNA glycosylases (UDGs) 
namely mitochondrial and nuclear uracil N’-glycosylase (UNG1 and UNG2 respectively), 
single strand selective monofunctional uracil DNA-glycosylase (SMUG1), thymine DNA 
glycosylase (TDG), and methyl-binding domain protein 4 (MBD4) (3,4,50). These 
glycosylases vary from each other with respect to preferred sequence context, type of DNA 
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(single or double stranded), cell cycle expression, and whether  Ura is an U:A or U:G. These 
enzymes are discussed in detail below Table 1-1 (41). 
Table 1-1: Mammalian DNA glycosylases (adapted from (41)) 
Enzyme Subcellular 
localization 
Functionality Substrates Knockout mice 
outcome 
Human 
disease 
UNG2 Nuclei Monofunctional 
(M) 
U, 5-FU in 
ss and ds-
DNA; U:A 
& U:G 
context 
(alloxan, 5-
hU, 
isodialuric 
acid) 
Partial defect in 
CSR, skewed 
SHM, B-cell 
lymphomas 
Complete 
defect in CSR, 
HIGM 
syndrome, 
infections, 
lymphoid 
hyperplasia 
UNG1 Mitochondria M Same as 
UNG2 
Same as UNG2 Unknown 
SMUG1 Nucleus M 5-hmU, 
U:G>U:A>s
s-U, 5-FU, 
εC in ss and 
ds-DNA 
Viable and 
fertile, 
SMUG1/UNG/M
SH triple KO 
reduced 
longevity (51) 
Unknown 
TDG Nucleus M U:G>T:G 
(5-hmU 
dsDNA, 5-
FU) 
Embryonic 
lethal, epigenetic 
role in 
development 
Unknown 
MBD4 Nucleus M U:G and 
T:G, 5-hmU 
in CpG 
context 
(epsilon-C, 
5-FU in ds-
DNA)  
Viable and 
fertile, C to T 
transitions, 
intestinal 
neoplasia 
Mutated in 
carcinomas 
with 
microsatellite 
instability 
1.2.2.1.1. Uracil DNA N’-glycosylases 
UNG1 and UNG2 are generated by alternative promoter usage (PA and PB) and 
subsequent splicing of the transcript of the same gene for mitochondria and nucleus, 
respectively (52,53). The active site consists of highly conserved regions that catalyze 
glycosidic bond cleavage. Both isoforms share an identical catalytic domain but have different 
N’-terminal domains, which result in different cellular localizations. UNG2 operates in post 
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replicative base excision repair of misincorporated uracil. A study conducted by Kavli et al. 
revealed an exceptional high rate of catalytic turnover of human UNG2 in vitro (54). 
UNG2 shows a high preference for ss-DNA over ds-DNA and U:G over U:A. Though 
at a very low efficiency, UNG2 can also excise uracil analogues, like the synthetic 
chemotherapeutic drug- 5-FU, oxidized pyrimidines like 5-hydroxyuracil (5-hU), alloxan, and 
isodialuric acid. These analogues contain minor modifications at the 5’-position of their 
pyrimidine ring (54-56).  
UNG1 is expressed in all tissue types while UNG2 is more abundant in proliferating 
tissues, like small intestine, colon, thymus, and testis (49). The protein and mRNA levels of 
UNG2 are cell cycle dependent and are upregulated several fold in S phase, in which DNA 
replication takes place and the tendency of dUTP misincorporation is greater (57,58). 
Human UNG2 is found to take part in the mutagenic processing of uracil in antigen 
stimulated B-cells as induced by AID to initiate CSR and SHM (54). The mechanism is 
discussed briefly in the next major section. Nilsen et al. showed a high genomic uracil 
accumulation rate in the isolated nuclei of mouse embryonal fibroblast (MEF) cells obtained 
from UNG knockout mice with respect to MEF cells from wild-type mouse (35). 
1.2.2.1.2. Single-strand-selective monofunctional uracil DNA glycosylase1 
Single-strand-selective monofunctional uracil DNA-glycosylase (SMUG1) was 
discovered in Xenopus laevis and received its name for high binding affinity to Ura in single 
stranded DNA (59). It is active for both U:A and U:G in double strand and single stranded 
DNA (60,61). SMUG1 has a low turnover number compared to UNG, but can be involved in 
repairing premutagenic U:G lesions in non-replicating chromatin due it its high binding 
affinity to U:G substrate (62). SMUG1 acts as an immediate backup for UNG2 and is 
constitutively expressed during the cell cycle. In a study conducted by Doseth et al., SMUG1 
was shown to be essentially specific for ds-DNA in the presence of Mg
2+
 and other divalent 
salts, despite its name. The same study reveals that this enzyme, in particular, is 200-fold less 
efficient than UNG2 in removing uracil from ss-DNA in AID hotspot sequences in the 
immunoglobin (Ig) loci, thus making it inefficient in antibody diversification. SMUG1 is 8-
fold more efficient in mice than in human (63). 
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A unique ability of SMUG1 is to excise oxidized pyrimidines with bulky substitutions 
at the C5 position, such as 5-hydroxymethyluracil (5-hmU) and 5-formyluracil (5-foU). It is 
also able to excise the other uracil analogues (54,64,65). 
1.2.2.1.3. G/T mismatch specific Thymine DNA glycosylase 
TDG is an important mismatch specific glycosylase and is involved in epigenetic 
regulation during embryonal development. It removes uracil lesions from CpG islands in 
DNA (66). TDG shows high preference for U:G over T:G lesions and 5-methyl cytosine (5-
mC), and a low affinity towards U:A substrate (67). It has a much lower catalytic turnover 
than UNG2 and binds with high affinity to AP- sites until released by APE1 in the following 
step of the BER pathway (68-70). This makes TDG slower and less efficient than UNG2. In 
vitro studies conducted by Hardeland U. et al. show that SUMOylated (small ubiquitin like 
modifier) TDG loses efficiency to excise T:G substrate and promotes its detachment from the 
AP sites (reviewed in (3)). 
TDG is highly expressed in G1 and G2/M and found in low amounts in S-phase (70). 
TDG acts as the main backup to excise most of the modified pyrimidine rings that are actively 
removed by UNG and SMUG1 (reviewed in (3)). 
1.2.2.1.4. Methyl-CpG-binding domain protein 4 (Methyl-CpG-binding 
endonuclease 4) 
Methyl binding domain protein 4 is probably involved in epigenentic regulation in 
which it targets methylated CpG DNA (71). It purpotedly helps preventing mutagenesis from 
the spontaneous deamination of cytosine and 5-mC by removing U:G and T:G mismatches. In 
addition, MBD4 removes 5-FU, 5-mC, and ε-C opposite to G. Functional loss of MBD4 is 
associated with microsatellite instability and observed in various types of human cancer 
(reviewed in (3)). 
1.2.3. Mismatch repair pathway (MMR) 
Mismatch repair (MMR) proteins are recruited to repair single base mismatches and 
erroneous DNA replication loops (72). Defects in the MMR pathway increase mutation 
frequency and thus lead to oncogenesis. Human mismatch repair proteins vary with each other 
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in respect to substrate specificity and structure. MutS homolog 2/ MutS homolog6 
(MSH2/MSH6) heterodimer recognize both single base mismatches and defective 
insertion/deletion loops while MutS homolog 2/ MutS homolog3 (MSH2/MSH3) heterodimer 
mostly binds to loops. Human MLH1 and post-meiotic segregation protein 1 (PMS1) or 
PMS2 act downstream of MSH2/MSH6 by forming a heteroduplex and migrate towards the 
end of a free the 3’-OH. In bidirectional MMR, if a nick is positioned at the 5’-end, then 5’-
>3’ exonuclease I (EXO1) degrades the strand from the damage site. If a nick is in 3’-
position, MLH1/PSM2 nicks a 150-nucleotide long stretch of DNA and EXO1 subsequently 
digests the strand.  RPA and PCNA recruit Polδ/ε to finish the polymerization process and 
DNA is ligated by LIG1 (Figure 1-4). 
 
Figure 1-4: Visual summary of mismatch repair pathway. MSH2/MSH6 recognizes 
mismatches and MSH2/MS3H binds to loops. PMS1 or PMS2 act downstream of 
MSH2/MSH6 by forming a heteroduplex and migrate towards the end of a free 3’-OH.  5’-
>3’ EXO1 degrades the strand from the damage site and DNA is ligated by LIG1 (Krokan-
Kavli, 2004) 
Defects in MMR proteins are found in several cancer types including hereditary non-
polyposis colon cancer (HNPCC). A hallmark of HNPCC is microsatellite instability that is 
less frequently found in sporadic colon cancers. Mutations in MLH1 and MSH2 are found in 
almost 60% and 35% of genetically characterized HNPCC cases. 
The MSH2/MSH6 heterodimer plays an important role in somatic hypermutation in 
which it recognizes U:G mismatch and converts it to A:T mutations by error prone translesion 
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synthesis (TLS) polymerase, Pol eta (Pol η). Recent findings reveal the importance of MMR 
proteins in a mouse cohort study. Triple knockout mice (UNG
-/-
SMUG1
-/-
MSH2
-/-
) have 
relatively much shorter life span than single (UNG
-/- 
or SMUG1
-/- 
or MSH2
-/-
) and double 
knockout mice (UNG
-/-
SMUG1
-/-
) (51). Thus, it could be said that MMR proteins can be 
considered as the last line of defense in uracil processing. 
1.2.4. Mutagenic uracil processing in adaptive immunity 
U:G mismatches are necessary for proficient adaptive immunity, but deleterious if left 
unrepaired in a normal stretch of genome other than the Ig genes. In response to antigen 
stimulation, the B-cell specific AID triggers class switch recombination (CSR) and somatic 
hypermutation (SHM) by targeted cytosine deamination within the recombined Ig gene locus 
(73).  The derived uracil is then carried forward via replication or processed by error-prone 
repair giving rise to mechanisms that generate very specific antibodies (SHM) with different 
effector functions (CSR).  
To initiate SHM, AID works on ss-DNA by introducing U:G mismatches in the switch 
region (S) and variable region (V) of Ig loci. The uracils are recognized and excised by UNG2 
creating abasic/ AP sites in the respective Ig regions. These AP sites are subjected to three 
different fates: <a> error-free BER restoring original sequence by insertion of the correct base 
by a DNA polymerase in a multi-step mechanism <b> generation of any possible mutation by 
using AP-sites as template during replication, which enables the insertion of any base and any 
possible transition and transversion at the C:G pair; <c> nicking of the AP-site by APE1 or 
APE2 and successive gap filling by low-fidelity polymerases (74) (reviewed in (3)). 
CSR depends on generation of  single stranded breaks in DNA at the S- region of Ig 
loci most likely in the G1-phase of cell cycle (75). UNG2 initially removes the uracil 
generating AP-sites that are next nicked by APE1 and APE2 to yield single stranded breaks 
(76). These breaks arise in two separate S regions and are joined by non-homologous end 
joining (NHEJ) to give rise to switched isotypes. The next step follows by converting the 5’ 
and 3’ overhangs into blunt end by EXO1 (Figure 1-5). 
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Figure 1-5: Model of somatic hypermutation and class switch recombination 
1.2.5. Pathophysiology- Role of AID and glycosylases in tumorigenesis 
AID is considered the “master molecule” for uracil generation in the Ig genes in adaptive 
immunity (77). AID, which is not only expressed in germinal centre B-cells but also in cells 
of other tissues, has several pathophysiological conditions related to mutation of the AICDA 
gene (78). Figure 1-6 shows the different physiological roles of AID. Details are explained in 
the subsequent sections. 
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Figure 1-6: Physiological and pathophysiological function of AID (79) 
1.2.5.1. Types of hematological malignancies and hyperplasia 
B-cell malignancies are marked by the presence of chromosomal translocation 
between an Ig locus and a proto-oncogene, and the consequences are dysregulated CSR (80). 
Studies conducted on c-myc overexpressing and BCL-6 overexpressing transgenic mice 
indicate that AID induced deamination in the B-cell germinal centre during antibody 
diversification lead to lymphomagenesis (81). Experiments conducted by Dorsett Y. et al 
show that AID is an indispensible molecule in the translocation between c-myc and IgH 
variable region subsequently leading to hyperplasia. Removal of the enzyme from malignant 
B-cell lines lessens the occurrence of chromosomal breaks and rearrangement in the 
transcription start sites and decreases elevated levels of transcription-coupled deamination in 
ss-DNA (82). However, mice models with AID gene knockout exhibit a reduced mutation rate 
in connection to B-cell lymphomas (83) (reviewed in (43)). 
Studies have revealed 180,000 different types of rearrangements from about 400 
million B-cells. To name some general types are: Mantle zone lymphoma is associated with 
bcl-1/Ig translocations, follicular lymphoma with bcl-2/Ig translocations and c-myc/Ig 
translocation is found in Burkitt’s lymphoma (80) (reviewed in (43). Mouse model studies 
suggest that AID is overexpressed in cells affected by infections, which may consequently 
give rise to B-cell lymphoma (by Epstein Barr virus), gastric carcinoma (H. pylori) (84), and 
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liver cancer (HCV). Apart from this, ubiquitously expressed AID leads to only T cell 
malignancies in some mouse models (reviewed in (43)). 
1.2.5.2. Somatic hyperplasia/ Kataegis 
Mutations at C:G base pairs are prevalent in most common types of human cancer. 
Cytosine deamination leading to U:G mismatches or translesion bypass of an abasic site give 
rise to C to T transitions, C to G transversions, and less frequently C to A transversions, 
particularly on TCA, TCC, and TCT contexts (85).  
The majority of the APOBEC family members may potentially cause cytosine 
deamination in DNA leading to cancers in breast, bladder, thyroid, cervix, lung, acute 
lymphoblastic lymphomas, multiple myeloma, chronic lymphocytic leukemia, and B-cell 
lymphomas. Certain types of malignancies do not have APOBEC mutational signatures, but 
develop from heavy carcinogenic exposures e.g. melanoma, small cell lung cancer and others 
(85) (reviewed in (43)). 
Kataegis is a Greek term meaning rainfall that refers to a pattern of localized 
hypermutations characterized in some cancer genome (85). High deaminase expression in 
yeast cells demonstrated the direct link between APOBEC proteins and the kataegis clusters 
(86). Several malignancy studies have revealed a unique observation of regional localized 
hypermutations in the same strand of a cancer related gene and its association to genomic 
rearrangement. These hypermutations most commonly are linked to C to T transitions and C 
to G transversions (85) (reviewed in (43). 
1.2.5.3. Physiological deficiencies 
AID deficiency is associated with a hyper IgM phenotype. Mutations in the UNG gene 
cause impaired CSR with partial SHM deficiency in some types of the hyper IgM syndrome. 
Both SHM and CSR are impaired in AID-deficient patients, but individuals with UNG 
deficiency generate an altered SHM with no or reduced CSR. UNG deficiency is likely related 
to malignancy, as in the absence of UNG, Ura is accumulated as an end product which is 
supposed to initiate mutation (as shown in Figure 1-3). Studies show that UNG deficient mice 
likely exhibit lymphatic hyperplasia and develop B-cell malignancies at very high rates (87). 
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1.2.5.3.1. HIGM syndrome 
HIGM syndrome is a rare hetergenous disorder (1/500,000 births) that is directly 
linked with normal or abundant level of low affinity IgM along with reduced or null serum 
concentrations of IgG, IgA, and IgE. These patients suffer from impaired CSR and variable 
consequences of SHM leading to recurrent respiratory tract infections and digestive disorders 
(88,89). 
These patients are grouped into several types: HIGM2 with AID deficiency following 
defective CSR and deficient SHM, HIGM5 with UNG2 deficiency exhibiting reduced SHM, 
and the third variant with mutation in the C-terminal AICDA gene following preserved SHM. 
Other types include CD-40 deficiency, CD-40 ligand deficiency, and NEMO deficiency 
syndrome. Treatments for these patients include intravenous Ig doses (60). 
1.2.6. Previous attempts to measure genomic uracil 
Uracil in the genome is far less abundant than the four canonical bases A, T, G, and C 
and therefore difficult to directly quantify. Several indirect and direct attempts have been 
made to quantify genomic uracil (32). 
1.2.6.1. Indirect approaches 
Andersen et al. carried out an indirect size dependent alkaline elusion assay to 
quantify dUMP incorporation in UNG
+/+
 and UNG
-/-
 mouse embryonic fibroblast (MEF) 
DNA following the assay protocol from Kohn et al. (90). Alkaline elution works by forcing 
DNA in a cell lysate through a filter under alkaline pH that separates DNA fragments of 
different sizes as a function of time. DNA from MEF cells was pretreated with UNG∆84 (a 
recombinant human UNG enzyme that lacks 84 amino acids in the N'-terminal) to excise 
uracil (10). Subsequent cleavage of the AP-sites by T4 endonuclease was used to introduce 
single stranded breaks (SSB) in DNA. Next, alkaline elution was performed to detect the size 
of DNA fragments. Thus the fragments eluted were compared to an untreated DNA sample. 
This method has a drawback as AP-sites can be formed spontaneously which hinders the 
actual measurement of uracil content in DNA. 
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Horvath et al. used a single-step real time PCR based method to quantify genomic 
uracil on synthetic DNA and genomic DNA from E.coli and mouse cell lines with perturbed 
thymidylate synthesis. They used wild type P. furiosus polymerase that halts immediately 
when encountered with Ura. They had a control polymerase from the same source that lacks 
the uracil specific catalytic site in it. Results from synthetic DNA were verified by direct 
isotopic measurements. By using different sets of primers, they analyzed the heterogeneity of 
Ura distribution throughout the genome (91). This assay has low sensitivity compared to 
others methods used to measure Ura, which marks one of the major disadvantages of this 
method. Another drawback is that it produces relative measurement of uracil. 
 A luminescence technique had been undertaken by Atamna et al. to measure uracil in 
DNA.  They incubated the DNA from cell lines with UNG to create AP-sites which were then 
treated biotin-containing aldehyde-reacting prove (ARP) that binds irreversibly to AP sites. 
These cells were lysed and the isolated DNA was treated with horse-radish peroxidase (HRP) 
that forms a HRP-DNA complex with the biotin. HRP-DNA adduct was separated by treating 
them with free avidin-HRP complex and precipitating DNA with DNA precipitating dye. A 
chromogenic assay was then performed to measure the number of AP sites by the 
luminescence activity of HRP (92). 
1.2.6.2. Direct approaches 
Direct methods of uracil quantification, excised in vitro by UNG, or deoxyuridine 
(dUrd) employ mass spectrometric detection of these small molecules with different initial 
chromatographic separation procedures. Measurement of dUrd has certain advantages over 
Ura as the former contains N’-glycosylic bond which on fragmentation produces Ura. A 
higher energy is needed to break Ura which increases the background during quantification. 
UNG excision has certain disadvantages in the quantification method: it has been 
previously reported that UNG has a substrate preference of single-strand over double strand 
DNA, U:G pair over U:A pair, and an explicit sequence preference. Moreover, buffer 
compositions can have an adverse effect on the enzyme activity. Mashiyama et al. performed 
a linearity testing by using increasing concentrations of the same genomic DNA extracted 
from lymphocytes that were pre-treated with restriction digestion enzymes that makes the 
DNA more fragmented thereby decreasing the chance of supercoiling and making its 
otherwise obscured uracil moieties easily accessible for UNG (93). In the experiments 
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conducted by Ren et al., a 198-bp long DNA had been PCR amplified using dUTP instead of 
dTTP that counts uracil in one-fourth fraction with all other bases (94). Therefore, the uracil 
content in this oligomer is drastically higher than that in genomic DNA. At the same time, it is 
unclear whether UNG acts with the same efficiency on an oligomer than on a natural genomic 
DNA. Burns et al. measured genomic Ura by HPLC-ESI+-MS/MS method from the UDG 
treated DNA obtained from breast cancer cell lines and spiked with (+6) heavy labeled Ura 
(
13
C and 
15
N) (95).  
Hydrolysis of DNA has been used by Chango et al. and Dong et al. to measure 
deoxyuridine by liquid chromatography coupled single mass spectrometry and liquid 
chromatography coupled tandem mass spectrometry, respectively (96,97). 
The analysis of dUrd has been a challenge because of the relative abundance of 
naturally occurring (
13
C)-2’-deoxycytidine (13C-dCyd) which is isobaric to and MS 
indistinguishable from dUrd. The relative natural abundance of (
13
C) is approximately 1.1% 
of all carbons (98). As dCyd elutes first from the column and there is a tendency to collect a 
considerable amount of dCyd with dUrd, therefore, only reverse-phase chromatographic 
separation is insufficient as dUrd signal overlaps with the (
13
C)-dCyd peak tail. This difficulty 
was successfully overcome by Galashevskaya et al., in 2013. They introduced a precursory 
HPLC step with a reverse-phase chromatography column (brand name Primesep 200) prior to 
reverse phase C18 column chromatography coupled tandem mass spectrometer. It has been 
reported using their assay that dUrd count in UNG 
-/-
 mouse embryonic fibroblast (MEF) 
DNA is 5-fold higher than that of UNG 
+/+
 MEF DNA and 11-fold higher in UNG2 mutated 
human lymphoblastoid cell lines than in normal UNG2 functional lymphoblastoid cells. They 
report lower basal genomic uracil level than previously measured by other groups (38). 
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1.3. Aim of the study 
The focus of this thesis was to calculate the amount of uracil excised by the activity of 
different glycosylases. We measured the activity using different substrates to elucidate the 
substrate specificity of different glycosylases present in different organs of UNG
-/- 
and 
UNG
+/+ 
mice. Genomic uracil was also measured on the same organs by LC-MS/MS and the 
number of uracil moieties present per 10
6
 deoxynucleosides has been quantified. Finally, we 
correlated genomic uracil and UDG activity to ascertain to what extent glycosylase activity is 
related to the number of uracil present in the genome. 
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2. Materials and methods 
2.1. Genotyping of transgenic mice 
2.1.1. Method of genotyping 
Background- Genotyping confirms whether the transgenic mice are wild-type, heterozygous 
or knockout. 
Procedure- Ear clips obtained from Balb/C UNG
-/- 
and UNG
+/+ 
transgenic mice (35) were 
subjected to DNA isolation using Qiagen Blood and Tissue kit (Qiagen, Germantown, MD, 
USA) according to the manufacturer’s instruction. The concentration of DNA was measured 
by Nanodrop ND-1000 spectrophotometer (Thermo Fisher scientific, Waltham MA, USA). A 
final volume of 20 µl contained 2 µl of 2-50 ng/µl of DNA, 1 U Platinum Taq polymerase 
(Invitrogen, Eugene, OR, USA), IX Platinum Taq buffer, 1.5 mM of MgCl2, 0.2 mM dNTP 
mix (Finnzymes, Espoo, Finnland) and 0.2 µM of forward and reverse primers (forward 
primer- 5’-GGCCACCCTGACAAATCCC-3’and reverse primer- 3’-
CACGGACCTAATCAAGCTCACG-5’) (obtained from Sigma-Aldrich, St. Louis, MO, 
USA). The thermal cycler parameters are as follows in Table 2-1: 
Table 2-1: PCR parameters 
Initial denaturation 98
o
C 30 seconds 
Denaturation 98
o
C 10 seconds 4
30 
cycles 
Annealing 65
o
C 30 seconds 
Elongation 72
o
C 2 minutes 
Final elongation 72
o
C  
Agarose gel was prepared by using 2% w/v of agarose, 1X Tris- acetic acid-EDTA (TAE) 
buffer and 5000X gel red. 5 µl of the PCR products were mixed with 1 µl of Biotium 6X 
loading dye (0.25% bromo-phenol-blue and 30% glycerol) and electrophoresis was performed 
with 1X TAE buffer at 100V for 25 minutes and analyzed on a Gel Logic 200 imaging system 
by Kodak Molecular Imaging software (Kodak, Rochester, NY, USA). 
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2.2. Mice selection and organs harvest 
After strain determination by PCR, three UNG 
+/+
 and UNG 
-/-
 mice were selected. 
These mice were euthanized by cervical dislocation and their organs were harvested at the 
quarantine animal laboratory. Organs include kidney, liver, brain, lung, muscle, and intestine.  
2.3. Preparation of protein extract 
2.3.1. Background 
Protein extracts prepared from tissues by homogenization was used for measuring 
different glycosylase activities. The tissue extracts contain all type of proteins including uracil 
DNA glycosylases, which when incubated with uracil-containing DNA/oligomer in vitro at 
physiological conditions excises the uracil that is measured using two different methods as 
described in the following sections. Proteins may become denatured, unfolded, or damaged 
during extraction and purification. To maintain a physiological pH, Tris-HCl and KCl were 
used as components in our buffer solution. Osmolytes like glycerol stabilizes the 
conformation of protein while in store thus rendering equal in vitro enzymatic activity when 
in reaction under physiological conditions. Non-ionic detergent NP-40 is less harsh on the 
protein than other ionic detergents during extraction and minimizes loss of enzymatic activity 
during analysis. At lower concentrations, dithiothreitol (DTT) reduces the disulphide bonds 
and maintains the reduced monothiol state of the protein. Thus in vitro, DTT stabilizes the 
free sulfhydryl bonds of the enzyme and restores its activity which could be lost by oxidation. 
Protease inhibitors inhibit the activity of proteases that could otherwise digest the proteins 
during purification. Tissue homogenization was achieved by passing the buffered tissues 
through needles of two different diameters to ensure absolute lysis. The concentration of 
protein was measured at 595 nm by the Bradford assay. This is a colorimetric protein assay 
that measures the absorbance shift of the dye coomassie brilliant blue G-250 which gradually 
turns blue from its original red color, in acidic conditions. The positively charged amine 
groups of the protein binds to the negatively charged dye molecules by ionic interaction that 
produces the intensity of the blue color of the dye. Therefore, the intensity varies with the 
number of amino groups present in the protein.  
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2.3.2. Procedure 
We used two standard lysis buffers for protein isolation of which the first buffer 
consisted of 10mM of Tris-HCl and 200mM of potassium chloride (KCl) and the second 
buffer contained 10 mM of Tris-HCL, 200 mM of potassium chloride, 40% glycerol and 0.5% 
NP-40. To 1 ml of each these buffers 0.001 µg of DTT, 1 µl of 1X complete, protease 
inhibitors- protease inhibitor cocktail 2 (PIC2) and protease inhibitor cocktail 3 (PIC3) were 
added. Each buffer complete were added in equal volumes, the amount being 0.6 µl of each 
buffer per 1 µg of tissue. With each addition of buffer, the mixture was minced by scalpel, 
thoroughly vortexed and subjected to homogenization through 21G and 25G needles. 
Reaction tubes were maintained on ice throughout the process. Homogenized extracts were 
incubated for two hours at 4
o
C and then centrifuged at 13.200 rpm for 15 minutes at 4
o
C to 
precipitate the cell debris. Supernatant containing protein was collected and concentration was 
determined by Bradford assay (Bio-Rad) using bovine serum albumin (BSA) as standard. 
Tissue extracts were aliquoted, snap frozen in liquid nitrogen and stored at -80
o
C. The 
purpose of aliquoting was to retain the enzyme activity intact in the extract and to use each 
aliquot tube only once during the assay.  
2.4. UDG activity assay 
2.4.1. 
3
H Ura release assay to measure glycosylase activity 
2.4.1.1. Principle 
Kavli et al. described the UDG activity assay which is employed in our experiment to 
measure UDG activity in our tissue extracts (54). The principle of this assay is to incubate a 
specific amount of tissue/cell extract with nick-translated calf thymus DNA containing 
tritiated dUMP (
3
H-dUMP), specific to U:A. and then to precipitate the DNA and protein 
reaction mixture in order to measure the liberated 
3
H-Ura excised by the present glycosylases 
in the extract. The amount of excised 
3
H-Ura measured by radioactive tritium decay in a 
scintillation counter relates to the amount of glycosylase present in the extract and their 
efficiency to initiate BER by excising uracil. The concept behind scintillation is to incorporate 
the measuring substance into a scintillation fluid- consisting of solvent and scintillators. 
Radioactive decay of the radio-substances present in sample constantly emits β-particles that 
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excite the scintillator which can then be measured by a very narrow range of electromagnetic 
radiation (light) in a scintillator counter. In our case, the tritium present in uracil moiety is the 
source of radioactivity. We measured glycosylase activity from the obtained disintegration per 
minute (DPM) values. 
2.4.1.2. Procedure 
Briefly, the protocol uses a total volume of 20 µl of assay mixture containing 5 µg of 
tissue extract and 1.8 µM of nick translated 
3
H-dUMP-labeled calf thymus DNA (specific 
activity 0.5 mCi/µmol) in 1X UDG buffer. The 1X buffer mixture contains 20 mM Tris-HCl, 
pH 7.5, 60 mM NaCl, 1 mM DTT, and 0.5 mg/ml of BSA. The reaction mixture was 
incubated for 10 minutes at 30
o
C and terminated by placing on ice. Next, 50 µl of 1 mg/ml 
salmon sperm DNA carrier (in 10 mM Tris-HCl, pH= 7.5 and 1 mM EDTA) and 500 µl of 
fresh ice-cold 5% trichloroacetic acid (TCA) were added subsequently and incubated on ice 
for 10 minutes to precipitate DNA. The mixture was centrifuged at 13,200 rpm for 10 minutes 
at 4
o
C to separate precipitated DNA from (
3
H)-U containing supernatant. Ultimately, 500 µl 
of supernatant were added to 5 ml of Ready Protein+ Liquid Scintillation Cocktail (Beckmann 
Coulter). Acid-soluble tritiated uracil was quantitated in a scintillation counter by Tri-Carb 
2900TR liquid scintillation analyzer using Quantasmart v.2.02 software (Perkin Elmer, 
Waltman, MA, USA). 
2.4.2. Oligonucleotide UDG cleavage assay 
2.4.2.1. Principle 
In the oligonucleotide cleavage assay, the 5’-end is either labeled with radioactive 
phosphate (
32
P or 
33
P) or a fluorescent compound, whereas the damaged base (in our case 
Ura) is in the middle of the same oligonucleotide. The labeled oligonucleotide can be used as 
a substrate either in the single-stranded form or after annealing to a complementary strand. 
The single or double stranded substrate is then incubated with cell/tissue extract or purified 
glycosylase that will release the damaged base, leaving an apurinic/apyrimidinic site that can 
be cleaved with pipiridine. Next, the uncleaved substrate and the cleaved product strands are 
separated by 12% polyacrylamide gel electrophoresis (PAGE) and quantified, in our case by 
ImageQuant TL software (GE Healthcare). Figure 2-1 shows the resulting product and 
substrate band formed after PAGE. 
37 
 
 
Figure 2-1: Gel image showing subsequent substrate band and product band 
2.4.2.2. Procedure 
Double stranded U:G and U:A substrates were prepared by annealing a 6-flourescein-
amidite (6-FAM)-labeled 19 oligonucleotide long strand containing uracil to a complementary 
strand containing either A (match) or G (mismatch) opposite to Ura. The sequences of the 
mentioned substrates are listed in Table 2-3. 6-FAM is attached to the 5’-end of the oligo. A 
total volume of 10 µl assay mixture contains 20 nM oligonucleotide substrate with 15 µg (for 
double stranded substrate) and 5 µg (for single strand substrate) of tissue extract dissolved in 
UDG assay buffer. This reaction buffer contains 20 mM of Tris-HCl, 60 mM sodium chloride, 
1 mM EDTA, 0.5 mg/ml BSA, and 1 mM DTT. For each substrate, four sets of reaction tubes 
were prepared to measure the activity of different glycosylases. 1 µg of UNG inhibitor (Ugi) 
obtained from Bacillus subtilis phage PBS2 (99) and 4 µg of anti-hSMUG1-antibody 
(polyclonal PSM1 which was prepared in our lab) were added to inhibit endogenous 
glycosylases so as to measure SMUG1 and UNG activity in the respective tubes. In the third 
set of tubes, both types of inhibitors were added to observe the residual activity representing 
TDG and MBD4. The fourth set contained no inhibitors and measures the total UDG activity. 
Table 2-2 provides a summary of each of the tubes: 
 
 
 
 
 
substrate band: 19 mer 
product band: 9 mer 
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Table 2-2: Compositions in the four sets of tubes used during experiment: 
Tube A + PSM1- inhibits SMUG1, measures TDG and 
MBD4 activity but mostly UNG activity 
Tube B + Ugi- inhibits UNG, measures TDG and MBD4  
activity but mostly SMUG1 activity 
Tube C + PSM1 +Ugi- inhibits both SMUG1 and UNG 
and represents activity from TDG and MBD4 
Tube D Without any inhibitors to measure the total 
glycosylase activity 
The reaction mixes were incubated at 37
o
C for 35 minutes for U:G substrate, 70 
minutes for U:A substrate and 30 minutes for ss-U substrate. The reactions were stopped by 
placing on ice and immediately adding 50 µl 10% piperidine following heating at 90
o
C for 20 
minutes to denature DNA and cleave the AP-sites. Piperidine was vacuum evaporated for 60 
minutes at 60
o
C and redissolved with 30 µl of 60% loading buffer. Each 25 ml of 12% 
polyacrylamide gel contained 420 mg/ml of urea, 10X TBE (Tris-Boric acid-EDTA) buffer, 
12% acrylamide/bis (19:1); 0.1% of ammonium persulphate (APS) and 25 µl of 
tetramethylethylenediamine (TEMED) were added freshly during gel casting to ensure proper 
polymerization. Wells of the newly polymerized gel were washed with 0.5X TBE buffer and 
allowed to prerun for more than 20 minutes at 200V. Wells were washed again and samples 
were loaded to separate product and substrate by 12% polyacrylamide gel electrophoresis 
(PAGE). Subsequently, gel slabs were laser scanned on Typhoon Trio imager and quantified 
by ImageQuant TL software (GE Healthcare). 
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Table 2-3: Sequences of the different Ura substrates used in assay: (6’-FAM is attached to 
the 5’-end of each strand that together count 19 nucleotides.) 
Substrate Sequence 
U:G 5’-CATAAAGGUAAAGCCTGG-3’ 
3’-GTATTTCCGTTTCGGACC-5’ 
U:A 5’-CATAAAGGUAAAGCCTGG-3’ 
3’-GTATTTCCATTTCGGACC-5’ 
ss-U 5’-CATAAAGGUAAAGCCTGG-3’ 
T:G 5’-CATAAAGGTAAAGCCTGG-3’ 
3’-GTATTTCCGTTTCGGACC-5’ 
2.5. DNA isolation and genomic uracil quantification 
2.5.1. Background 
DNA was isolated from mice organs using Qiagen Blood and Tissue kit according to 
the manufacturer’s instruction. For complete lysis, tissues were passed through a homogenizer 
and a series of needles varying in diameter. DNA was eluted with milliQ water as it is a polar 
molecule and more soluble in water. Alkaline phosphatase treatment of the purified DNA was 
followed to dephosphorylate any cellular dUMP that might have been co-isolated during the 
procedure, which is considered as a source of background interference in absolute dUrd 
measurement. UNG∆84, a recombinant form the complete catalytic domain of human UNG2 
(100) was used to excise uracil from DNA prior to hydrolysis. Along with UNG∆84, HindIII 
restriction enzyme was added to allow fragmentation that makes the otherwise obscured uracil 
in DNA easily accessible to UNG. Later, the hydrolyzing enzymes DNase I, nuclease P1 
(DNA cleaved to short oligomers and single dNMPs) and alkaline phosphatase 
(dephosphorylating dNMPS to dNs) are used to convert DNA into deoxynucleosides. 
2.5.2. Procedure 
2.5.2.1. Isolation of DNA and removal of intracellular dUMP 
25 mg tissue (10 mg spleen) were suspended in 200 µl of buffer ATL and 5 µl of 
10mg/ml RNase A from Qiagen Blood and tissue kit (Qiagen, Germantown, MD, USA) and 
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with 0.7µl of 100mM tetrahydrouridine (THU) which is a deaminase inhibitor. Samples were 
then passed through Dounce homogenizers and though 19G, 21G, 23G and 25G needles, 
incubated at 37
o
C for 5 minutes. 20 µl of proteinase K was added next, incubated at 37
o
C for 
55 minutes and DNA was extracted by DNeasy kit over milliQ water. The concentration was 
determined by Nanodrop ND-1000 spectrophotometer (Thermo Fisher scientific, Waltham 
MA, USA). To remove of the intracellular 2’-deoxyribonucleotides, DNA was incubated in 
0.2 U/µl of alkaline phosphatase with 100 mM ammonium bicarbonate (pH 7.6) for 30 
minutes, precipitated in isopropanol and washed with 70% ethanol.  
2.5.2.2. Uracil excision, DNA hydrolysis and sample preparation 
 In a total reaction volume of 30 µl, 15 µg of DNA was buffered with 20 mM Tris-HCl 
(pH 7.5), 60 mM NaCl, 1 mM of DTT, 1 mg/ml of BSA and treated with HindIII and 0.075 U 
of UNG∆84 at 37oC for 1 hour to excise the uracil contained in DNA. This deuracilated DNA 
assists in calculating the rate of Cyt deamination during sample workup, though a probable 
disadvantage is it may increase the background if all the Ura present in DNA is not excised. 
In another reaction tube, the same parameters were maintained, except for the addition of 
UNG∆84 so as to keep the uracils in DNA intact. Then DNA was precipitated with 
isopropanol as described in the previous paragraph and resuspended with 30 µl of 100 mM 
ammonium acetate (pH 6.0), 1 mM MgCl2, 1 mM CaCl2, 2 U DNase I and 0.2 U nuclease P1, 
incubated for 30 minutes at 37
o
C. This step marks hydrolysis of the DNA. (2-
13
C;1,3-
15
N2)-
2’-deoxyuridine (13C-15N2-dU) was used as an internal standard (IS). Afterwards, the reaction 
was buffered in ammonium bicarbonate (pH 7.6) to achieve a final concentration of 100 mM, 
and incubated for 20 minutes at 37
o
C with 0.1 U alkaline phosphatase to remove the 
phosphate groups. Contaminants were precipitated by adding three volume equivalents of ice-
cold acetonitrile and centrifugation at 4
o
C for 30 minutes at 13,200 rpm. Supernatants were 
transferred to new tubes and vacuum centrifuged until dry at room temperature (RT). Finally, 
samples were dissolved in 100 µl of 10% acetonitrile in water.  
2.5.2.3. Preparative purification of dUrd 
Prior to LC-MS/MS, a precursory HPLC step was performed to purify dUrd and to 
separate from dCyd. The process was executed using a reverse phase column with weak 
acidic ion-pairing groups (Primesep 200, 2.1 mm x 150 mm, 5 µM, SIELC technologies, 
Prospect Heights, IL) and an Agilent 1100 series HPLC system, with a multiple wavelength 
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detector (Agilent Technologies, Waldbronn, Germany). Samples were stored at 4
o
C prior to 
injection. Each sample was injected with an injection volume of 30 µl in triplicates. The 
gradient buffer consisted of solution A (0.1% formic acid in water) and solution B (0.1% 
formic acid in methanol), that uses the following program with a flow rate of 400 µl/min: start 
ramping with 10% of solution B, ramping of 60% B for 2 minutes, again ramping of 60% B 
for 2.5 minutes, holding this setup for 7.5 minutes and re-equilibrating with 10% B for 2.55 
minutes. Fractions, containing dUrd and dU-IS, were collected which were centrifuged in 
vacuum at RT until dry. Dry pellets were re-dissolved in 25 µl of 5% methanol and water 
solution. 
2.5.2.4. Instrumentation and reaction conditions of LC-MS/MS 
Deoxyuridine was quantified by a LC-20AD high performance liquid chromatography 
system coupled (Shimadzu Corporation, Kyoto, Japan) to an API5000 MRM- tandem mass 
spectrometer (Applied Biosystems, Carlsbad, CA, USA). HPLC consisted of a Zorbax SB-
C18 reverse phase column (2.1mm x 150mm, 3.5µM, Agilent Technologies, Santa Clara, CA, 
USA), protected by a Zorbax Reliance guard column (4.6mm x 12.5mm, Agilent 
technologies). Each sample was injected with an injection volume of 20 µl. The gradient 
buffers consisted of solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in 
methanol), that uses the following program with a flow rate of 300 µl/min: 0.5 minutes of 
ramping with 5% of solvent B, ramping of 80% B for over 1 minute, ramping of 30% B for 2 
minutes holding this setup for 7 minutes and re-equilibrating with 5% B for 2.1 minutes. 
Results were analyzed on Analyst v.1.4.2 software (Applied Biosystems). 
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3. Results and Discussion 
3.1. Target selection 
3.1.1. Choice of mice 
Two mouse strains, UNG
+/+
 and UNG
-/-
, were used to estimate tissue specific 
glycosylase activity and to quantify deoxyuridine by LC/MS/MS analysis. The mice selected 
for analysis were age matched (6 months old). We collected three UNG
+/+
 and UNG
-/-
 strains 
and confirmed their genotypes by performing a PCR assay. We chose six proliferative and 
non-proliferative organs to check the glycosylase level in each of them: brain, small intestine, 
kidney, liver, lung and muscle. For the LC/MS/MS quantification, we included spleen as well. 
The spleen could not be used for glycosylase activity because the weight of the organ is less 
than what was calculated as necessary for protein and DNA isolation at the same time.  
 3.2. UDG activity measurement 
We present UDG activity in two types of measurements. For glycosylase activity 
measurement by 
3
H-Ura release, we report the units in the amount of Ura released per 
milligram of tissue extract (µmol Ura mg
-1
 min
-1
). In the glycosylase activity assay by 
oligonucleotide cleavage, specific glycosylase activity was measured and will be reported in 
nanomoles of uracil excised per minute per milligram of tissue extract (nmol Ura min
-1
 mg
-1
). 
First, we analyzed the percentage of substrate cleavage by dividing the intensity of the 
product band by the total intensity of the product and substrate band. Then, considering the 
other defined parameters we calculate 100% uracil excision. The value obtained from this 
calculation serves as a constant to calculate the number of uracil molecules excised by 
different glycosylase activity. The equation below uses U:G substrate, 35 minutes of 
incubation time and 15 µg of tissue extract for example: 
100 % specific glycosylase 
activity  
Total amount of  substrate (nmol Ura)
Total reaction time (min)
=
Amount of  protein (mg)
 
 
-4 -1 -1= 3.8x10  nmol Ura min  mg  
 
(where, substrate amount = 0.0002 nmol, reaction 
time = 35 mins @ 37 
o
C, protein amount = 0.015 mg) 
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For e.g., for 40 % specific 
glycosylase excision activity 
-4
-1 -140x3.8x10=  nmol Ura min  mg
100
 
 
-4 -1 -1= 1.52x10  nmol Ura min  mg  
 
This calculation assumes linearity with time, which is not actually the case for this assay.  
3.3. 
3
H Ura release assay to measure glycosylase activity 
In this assay, uracil has been introduced into a calf thymus DNA by nick translation 
that mimics uracil incorporated during replication in vivo. The dUMP of this long U:A 
substrate is radiolabelled (
3
H-dUMP). We started our experiments using Tris-buffer 
containing 10 mM of NaCl, 5 mM MgCl2, 1 mM CaCl2 that was prepared to serve as a  
universal buffer, for example, uracil excision, hydrolysis, etc. But we experienced low and 
unstable UDG activity with this buffer each time we measured. So, we tested different salt 
concentration in Tris-buffer to verify the best salt condition for UDG activity which is 
discussed in details in section 3.3.1.  
3.3.1. Testing of salt concentration in Tris-buffer solution 
The salt concentration may influence the enzyme activity. Firstly, it can affect the 
reaction equilibrium of binding DNA that in turn has an effect on the outcome of enzyme 
activity. Certain salts enhance or diminish the activity of an enzyme. Most importantly, the 
salt concentration may have an impact on the stability of the protein: enzymes are usually 
more stable in higher salt concentrations, but salts frequently either reduce or increase enzyme 
activity.  
We tested four different salt concentrations with increasing ionic strength of 
monovalent ions (0-60 mM NaCl) and addition of two divalent ions (Mg
2+
 and Ca
2+
) in one 
particular Tris-buffer. We used recombinant UNG∆84 to test different buffers which had been 
diluted the stock enzyme to 10
6
 with each of the four mentioned buffer compositions varying 
in salt concentration. While the experiments with UNG∆84 demonstrate that salt conditions 
do have an effect on the enzyme activity representing the major UNG, they might also 
influence SMUG1, TDG and MBD4 differently. This was not investigated due to time 
limitations. The final salt concentrations of these buffers are given in Table 3-1: 
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Table 3-1: Different salt concentration in 20 mM Tris-buffer (pH 7.5): 
Buffer 1 10 mM NaCl, 5 mM MgCl2, 1 mM CaCl2 
Buffer 2 20 mM NaCl 
Buffer 3 No salt 
Buffer 4 60 mM NaCl 
 
UNG activity increases with the increase in NaCl concentration of, in our case 
probably due to Na
+ 
(Figure 3-1). We observed the highest enzyme activity (2754 µmol Ura 
mg
-1
 min
-1
) with reaction buffer 4 containing 60 mM NaCl. The activity was lower with 
reaction buffers containing less salt or no salt at all (below 850 µmol Ura mg
-1
 min
-1 
for most 
cases). It has been previously reported that Mg
2+
 increases the activity of full length UNG2 
(101) and decreases UNG∆84 activity 2-fold. As UNG activity increases with the increase in 
Na
+
 concentration, we could have tested the impact of Mg
2+
 on higher NaCl concentration, 
but this was not performed.  
 
Figure 3-1: UNG∆84 activity in different salt conditions. The enzyme shows optimal 
activity in the presence of 60 mM NaCl 
It has been reported by Doseth et al. that Mg
2+
 does not significantly stimulate the 
activity of mouse UNG2 (63). Our samples were harvested from mouse and we selected 
buffer 4 to run the tissue extracts obtained by lysing different organs from mouse. This buffer 
4 is referred to as UDG buffer in rest of the text. 
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3.3.2. Measurement of glycosylase activity in different organs 
The tissue extracts used in this assay were obtained from the organs harvested from 
age matched mice that had been stored for three years at -80
o
C. However, the wild type and 
knock-out counterparts of all the organs were lost in storage. To obtain statistically significant 
results, we needed at least three mice from each of UNG
+/+
 and UNG
-/-
 strains. Initially, we 
had only selected organs from two UNG
+/+ 
mice and four UNG
-/-
 mice: heart and thymus from 
one UNG
+/+
, and muscle and heart from one UNG
-/-
 strain. We measured glycosylase activity 
of tissue extracts from both wild type and knock-out kidney, liver, heart, lung, and thymus 
and only from knock-out brain, stomach, intestines and muscle.  
 
Figure 3-2: Rate of Ura excision activity by glycosylases on 
3
H-Ura-DNA (long U:A 
substrate) in different organs from UNG wild-type and knock-out mice. 
Total glycosylase activity in different organs obtained from UNG
+/+
 and UNG
-/-
 strains 
is presented in Figure 3-2. The knock-out strains show very little or no glycosylase activity 
with long U:A substrate indicating that UNG is the major DNA glycosylase measured in this 
assay. An exception to this case is the thymus which has not investigated further due to time 
limitations. Therefore, we detected mostly UNG activity in these organs. In wild-type kidney, 
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liver, thymus and heart, there is relatively high amount of UNG activity whereas it is 
negligible for the knock-out counterparts. We measured activity in UNG
+/+
 lung and UNG
-/- 
brain, intestine, muscle and stomach as well, but we will not discuss that further as they lack 
their counterparts.  
Among all these organs, wild-type kidney shows the highest amount of glycosylase 
activity. We measured very high activity for the knock-out large intestine samples which were 
far higher than the wild type-kidney. It is supposed that while organ harvest, the large 
intestines were not properly washed and those were contaminated; it could be that we 
measured microbial glycosylase activity for these knock-out intestines. 
3.4. Oligonucleotide cleavage assay to measure glycosylase activity in new 
set of mouse organs 
The radioactive assay uses a long U:A substrate in which 
3
H-dUMP is incorporated 
into DNA instead of dTMP by nick translation. In the previous test we lacked the wild-type 
and knock-out counterparts of all the organs. In order to exhibit specific results from the 
activity of different glycosylases on different substrates, we performed the oligonucleotide 
cleavage assay. Another advantage of oligonucleotide cleavage assay is that it utilizes very 
small amounts of tissue or cell extract to measure activity. 
3.4.1. Protein concentration optimization 
We observed in the radioactive assay (section 3.3.3) that the wild-type kidney has the 
highest amount of glycosylase activity. We chose a wild-type kidney tissue extract as our 
optimization sample. We utilized reaction conditions that have been previously optimized for 
cell lines and established in our lab (data not shown): variable amounts of tissue extract of a 
new kidney sample were incubated with U:G substrate and 1 µg of anti-SMUG1 antibody 
(PSM1) for 10 minutes at 37 
o
C. PSM1 was included to quantify UNG (assuming that TDG 
and MBD4 contribute little to the total activity). Disappointingly, our experimental set up 
provided no signal for WT kidney, probably because the amount of extract used here 
contained too little UNG to act on 20 nM substrate (Figure 3-3). 
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Figure 3-3: UNG
+/+
 kidney shows very low or no glycosylase activity with a low amount 
of tissue extract. We measured UNG activity initially. 
We increased the amount of extract to 5 µg and 10 µg and incubated each at three time 
points: 10, 20, and 30 minutes, at 37 
o
C and did not add any inhibitor because we wanted to 
measure the total glycosylase activity from this optimization assay. We tested for three types 
of substrates: U:G, U:A, and single-stranded-Ura. It has been previously established in our lab 
that uracil excision activity within 10% to 70% is considered as the quantifiable range of this 
assay (data not shown). For U:A substrate, 5 µg of tissue extract incubated for the three 
mentioned time points: 10 minutes, 20 minutes, and 30 minutes, gives excision activity of 
13%, 21%, and 27%; and 10 µg of tissue extract excises 17%, 23%, and 30% of uracil at these 
respective time points. We planned to examine non-proliferative tissues like brain and muscle, 
which probably contain lower glycosylase activity than rapidly proliferative tissues (49). If we 
had used 10 µg of tissue extract and incubated for 30 minutes to run all our samples, then 
wild-type non-dividing tissues would not exhibit any detectable activity. So, we decided to 
increase the amount of protein to 15 µg and test different incubation times to produce an assay 
within the quantifiable activity range. 
Glycosylases showed a higher excision rate for U:G substrate than for U:A. 5 µg of 
tissue extract, incubated for the three respective time points, exhibited excision activity of 
27%, 44%, and 50% while 10 µg of tissue extract excises 30%, 55%, and 61% of Ura during 
the same duration. Rapidly dividing tissues such as the intestine likely contain high 
glycosylase activity. To keep the glycosylase activity of the proliferating tissues within the 
quantifiable range, we used 15µg of kidney extract and incubated at different time points to 
achieve the best level of activity that fits within the selected range.  
5 µg of kidney extract shows excision activity of 28%, 48%, and 62%, while 10 µg 
exhibits excision of 33%, 57%, and 70% for 10 minutes, 20 minutes and 30 minutes, 
respectively (Figure 3-4). Here, we find that 5 µg of protein incubated for 30 minutes fits 
within the quantifiable range of the assay while 10 µg incubated for the same duration almost 
reached the edge of saturation. Thus, we successfully optimized the amount of protein and 
 WT 
kidney 
+PSM1 
0.1 0.4 0.8 1.2 µg Blank 
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incubation time for single-stranded-Ura substrate. We continued running extracts from all the 
organs using 5 µg of protein and 30 minutes incubation time. 
 
Figure 3-4: Optimization of protein concentration. 5 µg and 10 µg of tissue extract from 
UNG wild-type kidney showing low glycosylase activity for U:G and U:A substrate. (a) is the 
quantification of (b).  
3.4.2. Reaction time optimization 
We incubated 15 µg of kidney tissue extract with different DNA substrates at different 
time points to find an optimal incubation time to run the rest of our samples. Glycosylases 
exhibit substrate preference of U:G over U:A and are also sequence dependent (63). So, we 
incubated the kidney extract for longer time with U:A substrate than with U:G. We found that 
for U:G substrate, 15 µg of kidney extract yields activity of about 40-65% for 15 minutes, 20 
minutes, 25 minutes, 30 minutes and 35 minutes respectively. Since, it has been demonstrated 
in this experiment that excision activity by 15 µg of tissue extract for 35 minutes of 
incubation time is within the quantifiable range of assay, we employed the mentioned reaction 
conditions to run all our samples for U:G substrate.  
Excision activity for U:A substrate was 30-55% for 30 minutes, 40 minutes, 50 
minutes, 60 minutes and 70 minutes of incubation time, respectively (Figure 3-5). Here, it has 
been showed that with 70 minutes of incubation time 15 µg of extract yield glycosylase 
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activity within the quantifiable range. Therefore, we ran all our samples according to this 
mentioned reaction conditions. 
 
Figure 3-5: Incubation time optimization. (a) 15 µg of kidney tissue extract from UNG 
wild-type kidney shows glycosylase activity within the quantifiable range of the assay for 
U:G and U:A substrate. (a) is the quantification of (b). 
3.4.3. Optimization of amount of inhibitors to be used 
UNG2 is the most important glycosylase with SMUG1 thought to be its immediate 
backup in proliferating cells (54). In order to differentiate between the activities of these two 
enzymes, we had to inhibit one enzyme at a time to check the activity of the other. To check 
the UNG and SMUG1 activities, we utilized in-house polyclonal anti-human SMUG1 
antibody to inhibit SMUG1 and Ugi (99) to inhibit UNG. The amounts of each of these 
inhibitors were optimized to ensure complete inhibition of the respective enzymes (Figure 
3-6).  
Both UNG and SMUG1 were inhibited with the highest amount of inhibitor added to 
them. Ugi which is obtained from Bacillus subtilis phage PBS2, is an irreversible inhibitor 
(102) that binds to the DNA binding groove of the catalytic domain of UNG thus restricting 
product binding to the enzyme. PSM1 is a polyclonal antibody that binds to specific epitopes 
in the active site of SMUG1 thus inactivating its catalytic activity. An increase in the 
concentration of inhibitors decreased the binding affinity of the enzyme to the substrate. With 
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increasing inhibitor concentration, more of these molecules irreversibly occupy the catalytic 
domain of the enzymes thereby decreasing the activity of binding substrates. We finalized the 
amount of inhibitors to be used for further assay: 4 µg of PSM1 and 1 µg of Ugi.  
 
Figure 3-6: Optimization of inhibitor concentration. (A.) With increasing concentration, 
both the inhibitors, Ugi and PSM1 completely inhibit UNG and SMUG1 activity, 
respectively. 
3.4.4. Glycosylase activity in mouse organs 
After initial experiments to establish methods, we tested all the tissue extracts using 
conditions, based on the initial results, which are summarized in Table 3-2.  
Table 3-2: Conditions used to run the oligonucleotide cleavage assay: 
U:G U:A ss-Ura 
15 µg tissue lysate 15 µg tissue lysate 5 µg tissue lysate 
4 µg PSM1 and 1µg Ugi 4 µg PSM1 and 1 µg Ugi 1 µg Ugi 
35 minutes incubation at 37
o
C 70 minutes incubation at 37
o
C 30 minutes incubation 
at 37
o
C 
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3.4.4.1. U:G substrate 
As mentioned earlier UNG is a major glycosylase in removal of uracil from DNA and 
at the same time shows some sequence preference of U:G over U:A in most sequence 
contexts. However, it is even more active towards single stranded DNA substrate (54,100). 
Our results support these findings. 
The UNG
-/-
 strain has previously been shown to have no detectable UNG activity and 
may largely be dependent on SMUG1 for uracil excision. This was, however, not 
demonstrated in the report on uracil DNA glycosylase activities in the initial paper, as no 
antibody inhibiting SMUG1 was available at that time (35). It has since been reported that 
SMUG1 is more abundant in mouse cell lines than human cell lines (63). Generally, we found 
considerable amounts of SMUG1 activity in the wild-type UNG genotype for U:G substrate. 
There was no clearly detectable amount of residual activity that could represent TDG or 
MBD4 activity in any of the wild-type and knock-out tissue extracts. These two enzymes 
most likely are not as important as UNG and SMUG1 in uracil excision of DNA, or have 
sequence preferences other than the ones used here, which may be why they could not be 
detected using this particular U:G substrate. 
We have compared the different glycosylase activities in each of the organs. We find 
that UNG is generally the major uracil-DNA glycosylase with all three substrates (U:G, U:A 
and ss-DNA) in all organs, but SMUG1 is apparently equally important, perhaps even more 
important, in some organs (Figure 3-7, Figure 3-8 and Figure 3-9). It is, however, possible 
that the Ugi concentration was not high enough to inhibit UNG completely in all organs. 
Generally, uracil-excision activities were roughly equal in the different organs, except small 
intestine that had high activity that probably saturated the assay system. Interestingly, small 
intestine appeared to have very high levels of UNG, but apparently no detectable activity of 
SMUG1 or other uracil-DNA glycosylases, as demonstrated by the lack of detectable 
substrate cleavage in UNG
-/-
 mice. When both inhibitors were present (Ugi and SMUG1 
antibody PSM1) essentially all detectable uracil-DNA glycosylase activity was abolished. 
Below follows a more detailed description for each organ. 
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Figure 3-7: Rate of excision activity of different glycosylases, obtained from different 
proliferative and non-proliferative tissues of UNG wild-type and knock-out mice, on 
U:G substrate. (A.) No inhibitors represent the total glycosylase activity, samples treated 
with Ugi account for SMUG1 activity, PSM1 samples provide the results for UNG activity 
while samples treated with both inhibitors show total TDG and MBD4 activity. UNG activity 
is higher in intestine and lower in brain in wild-type samples. SMUG1 is abundant in brain 
and not found in intestine. (a) is the quantification of (b) and the error bars represent the 
standard deviation of three biological replicates.  
i> Brain- In principle, activity in samples treated with Ugi should represent SMUG1 
activity, along with TDG and MBD4 activities, while samples treated with PSM1 
should show mostly UNG activity along with TDG and MBD4. However, we 
found no significant residual glycosylase activity that could represent TDG and 
MBD4 when samples were treated with both inhibitors, Ugi and PSM1. Therefore, 
SMUG1 and UNG are the only detectable uracil DNA glycosylases in brain and 
account for roughly the same amount of specific excision activity. Both the total 
glycosylase and SMUG1 activities of the wild-type brain were statistically 
indistinguishable from the knock-out brain (p= 0.49 and 0.43 respectively). The 
results show that SMUG1 is an important glycosylase in the brain as total 
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glycosylase activity in both strains accounts for almost an equal excision rate. We 
conclude that SMUG1 plays an important role in uracil excision in brain, possibly 
even more important than UNG (Figure 3-7).  
ii> Small intestine- In small intestine, we found no significant residual glycosylase 
activity that could represent TDG and MBD4 when samples were treated with both 
inhibitors, Ugi and PSM1. Moreover, there was also no apparent detectable 
SMUG1 activity which has been indicated by lack of product band formation in 
UNG
-/-
 mice; a statistical insignificant p value for SMUG1 activity being 0.06 
when both the strains were compared. Therefore, it is possible that the resulting 
product band we are detecting in Figure 3-7 has developed due to residual UNG 
excision activity. We hypothesize that intestine being a rapidly proliferating tissue 
contains high amount of UNG and that the Ugi added was not sufficient to inhibit 
all of it. Here, we conclude that rapidly proliferating tissues mostly depend on 
UNG to excise uracil lesion. 
iii> Kidney, liver and lung- UNG activity is quite higher than that of SMUG1 in all 
these three organs. In UNG
+/+
 strains, the total glycosylase activity in kidney, liver 
and lung were statistically distinguishable from their UNG
-/-
 counterparts (p= 
0.0005, 0.0004 and 0.003 respectively); while the SMUG1 activity in kidney and 
lung of the same strains were statistically insignificant with p values 0.6, and 0.07. 
We found statistically significant p value of 0.001 for the SMUG1 activity in liver 
of both these strains. The results suggest that UNG is the important enzyme for 
uracil excision in these organs and that the knock-out genotype employ SMUG1 as 
the immediate backup for UNG (Figure 3-7). 
iv> Muscle- In wild-type muscle, UNG and SMUG1 activity are almost similar. When 
the muscles of UNG+/+ and UNG-/- strains were compared with each other for 
total glycosylase activity and SMUG1 activity, the respective statistically 
indistinguishable p values were found to be 0.6 and 0.56. Results demonstrate that 
both UNG and SMUG1 are the equally important glycosylases to play roles in 
uracil excision (Figure 3-7). 
In our result, most of the total glycosylase activity does not show synergy between the UNG 
and SMUG1 activity levels. This has been reported before by Doseth et al. This apparent 
paradox is supposed to be caused by competition between SMUG1 and UNG for the same 
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substrate (63) . SMUG1 has a high affinity for U:G substrate and a very low turnover. This 
prevents catalytically efficient UNG from accessing the substrate. 
We encountered a large standard deviation for some of our samples, especially the 
lung and muscle. It is supposed that we faced handling faults during experiment by adding 
less amount of inhibitor to some of the tubes. 
As reported earlier, glycosylase activity is highest in rapidly proliferating tissues, 
higher in proliferating tissues and lower in non-proliferating ones (10,49). Here, we have 
intestine as the rapidly dividing tissue which counts for very high levels of UNG activity that 
the signal reached beyond the quantifiable range of the assay. Lung, kidney and liver, all of 
which are also proliferating tissues, exhibit high levels of both UNG and SMUG1 activity. 
But in brain and muscle, we found less UNG and more SMUG1 activity indicating the latter 
as the important glycosylase in less proliferative tissues. 
3.4.4.2. U:A substrate: 
We found considerable amounts of UNG activity in the wild-type UNG samples for 
U:A substrate. There was no clearly detectable amount of residual activity that could 
represent TDG or MBD4 activity in any of the wild-type and knock-out tissue extracts. These 
enzymes most likely are not as important as UNG in uracil excision of DNA, or have 
sequence preferences other than the ones used here, which may be why they could not be 
detected using this particular U:A substrate. We found that UNG is generally the major uracil-
DNA glycosylase for U:A substrate in all the organs and its activity is almost identical to the 
total glycosylase activity (Figure 3-8). SMUG1 has little to no affinity for this substrate in the 
sequence context mentioned in Table 2-3. So, it could be said that UNG is the chief enzyme in 
excising Ura from the U:A base-pair in DNA in the sequence context.  
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Figure 3-8: Rate of excision activity of different glycosylases, obtained from different 
proliferative and non-proliferative tissues of UNG wild-type and knock-out mice, on U:A 
substrate. (a) No inhibitors represent the total glycosylase activity while samples treated with 
PSM1 account for UNG activity. UNG activity is higher in intestine and lower in brain in 
wild-type samples. SMUG1 is abundant in brain and not found in intestine. (a) is the 
quantification of (b) and the error bars represent the standard deviation of three biological 
replicates.  
The small intestine is a rapidly dividing tissue which counts for very high levels of 
UNG activity that signal reached beyond the quantifiable range of the assay. Lung, kidney 
and liver, all of which are moderately proliferating tissues, contain relatively high levels of 
UNG activity. But, in brain and muscle, we found less extent of uracil excision as they have 
relatively less capacity of proliferation than the other mentioned tissues.  
3
H-dUMP release assay has been previously performed by Nilsen et al. using U:A 
substrate and Ugi as UNG inhibitor (35). In our experiment, we additionally introduced PSM1 
to test actual UNG activity. Our results confirm that there is no detectable signal for UNG 
activity in the knock-out kidney and liver.  
3.4.4.3. Single-stranded Ura substrate 
To measure different glycosylase activity in ss-Ura substrate, we used two sets of 
tubes one comprising of no inhibitors and the other with Ugi to inhibit UNG activity. It has 
been previously reported that SMUG1 prefers ss-Ura substrate in presence of divalent cations 
(63). But we did not add any divalent salt to our buffer mixture. As a result, SMUG1 was 
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inactive on ss-Ura substrate and we did not check this by pre-incubating our samples with 
PSM1. TDG or MBD4 are not active on single stranded DNA. We have compared the UNG 
activity in each of the organs (Figure 3-9). 
There was no detectable amount of activity in the Ugi treated and untreated samples 
from all the organs of UNG null mice. Therefore, it has been confirmed that SMUG1 does not 
act on single strands in presence of only monovalent cations (in our case Na
+
). So, these mice 
are unable to eliminate Ura from single stranded DNA. We did not find any SMUG1 activity 
either for the wild type samples treated with Ugi. 
We encountered variable detectable amounts of glycosylase activities in all the organs 
of UNG
+/+
 mice. It has been previously reported that glycosylase activity ss-Ura substrate has 
a considerable amount of advantage over double stranded substrates (54,100). Wild type brain 
and muscle exhibited least amount of UNG activity than the other tested organs. These two 
tissues consist of non-dividing cells that likely contain less glycosylase activity in them. 
Likewise, the small intestine is lined with highly proliferative epithelial cells which show the 
highest UNG activity. The signal from this organ is in saturation and might have reached 
beyond the quantifiable range of the assay. The kidney, liver and lung have almost a similar 
range of glycosylase activity present in them. We encountered very nominal range of standard 
deviation within the replicates of all the organs (Figure 3-9). 
 
Figure 3-9: Rate of excision activity of different glycosylases, obtained from different 
proliferative and non-proliferative tissues of UNG wild-type and knock-out mice, on ss-
Ura substrate. (a) UNG activity is higher in intestine and lower in brain for wild type 
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samples. (a) is the quantification of (b) and the error bars represent the standard deviation of 
three biological replicates.  
3.4.4.4. T:G substrate 
It has been previously reported that TDG exhibits preferences for T:G mismatches 
(67). As we have explained the results of U:G, U:A and single stranded-Ura substrates in the 
previous sections, we concluded that brain has the low amount of total glycosylase activity 
while it is highest for small intestine. We measured the TDG activity in 15 µg of tissue 
extracts of these two organs from wild-type mice using 20 mM of T:G mispair substrate. We 
selected three incubation time points for this assay: 60 minutes, 90 minutes and 120 minutes 
at 37
o
C. No APE1 was added into the reaction mixture.  
A weak TDG activity has been illustrated in both wild-type kidney and brain samples 
(Figure 3-10). The activity is below the quantifiable range for both the organs. As TDG has a 
low catalytic turnover, it requires APE1 to nick the abasic site that in turn helps the enzyme to 
dislodge from DNA. A likely explanation for this apparent paradox is that the tissue extract 
did not contain enough APE1 needed to displace TDG from its substrate. So, the enzymes 
could not access all of the provided mismatch substrates. 
 
 
Figure 3-10: Rate of excision activity of TDG, obtained from different proliferative and 
non-proliferative tissues of UNG wild-type, on T:G substrate. (a) No activity was found 
for either of the organs. (a) is the quantification of (b) and the error bars represent the standard 
deviation of three biological replicates.  
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3.5. Quantification of genomic uracil in different organs by LC/MS/MS 
3.5.1. Quantification results 
dUrd measurement in various organs from UNG 
+/+
 and UNG 
-/-
 mice were obtained 
from Sarno A. Here, we report total dUrd per million deoxynucleotides. Referring to the 
graph in Figure 3-11, it is clear that there is large standard deviation for most of the organs. 
This was due to the loss of replicates of some organs during quantification procedure. Another 
probable reason for this high standard variation may be due to error that has arisen from 
different instruments. Two different LC/MS/MS instruments were used during the assay 
period. It has been postulated that UNG 
-/-
 mouse contain a considerably high amount of uracil 
in DNA that the UNG 
+/+
 mouse. 
 
Figure 3-11: Deoxyuridine measurement in different proliferative and non-proliferative 
tissues obtained from UNG wild-type and knock-out mice. 
3.6. Correlation between oligonucleotide cleavage assay and LC/MS/MS 
quantification to measure uracil in different organs of mice 
We have plotted dUrd/10
6
 dNs against nmoles Ura min
-1
 mg
-1
 to correlate between the 
glycosylase activity and the number of uracil molecules present in DNA. We observed no 
correlation between these two parameters. There are two main reasons that might explain our 
unsuccessful correlation graph (Figure 3-12): 
i> There was a loss of sample during the dUrd measurement assay due to the error in 
LC/MS-MS. The replicates show much variation and thus prove inaccurate. 
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ii> There might not be any biological correlation between the dUrd levels and 
glycosylase activity.  
a. We observed quite high levels of glycosylase activity in all the tested organs 
from wild-type mice. The values of dUrd are too low, so there must not be any 
genomic Ura stress in DNA. 
b. Glycosylases are responsible for removal of Ura from DNA. But the factors 
that introduce Ura might be more directly related its levels in DNA. To 
properly correlate levels of Ura in DNA, we have to test AID, that deaminates 
Cyt, and test whether increases in nuclear concentration of AID increase Ura 
levels in DNA. The second most important factor is cellular concentration of 
dUTPase and TS that aid in misincorporation of Ura in DNA. This obviously 
depends on the dUTP/dTTP pool of the cell. To plot correlation, we need to 
check if the levels of these two enzymes are down-regulated that increases Ura 
levels in DNA. 
c. Lastly, we need to test the MMR protein levels in cell. Decrease in the 
concentration of MMR protein could lead to elevated levels of Ura in the 
genome. 
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Figure 3-12: Correlation between deoxyuridine measurement and rate of glycosylase 
activity in different proliferative and non-proliferative tissues obtained from UNG wild-
type and knock-out mice. 
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4. Conclusion 
Activities of uracil-DNA glycosylases depend on the physiological salt concentration, 
distinctive preferences over various sequences and of course the nature of cell division in the 
tissue. The relative contribution of UNG, SMUG1, TDG and MBD4 in removal of genomic 
uracil from different normal mouse organs has not been investigated before. Our results reveal 
that SMUG1 has a very strong preference for U:G substrate and is not active on U:A or ss-Ura 
in the presence of optimal amount of monovalent salt (NaCl) . TDG and MBD4 do not exhibit 
any activity under the given reaction conditions. UNG excises ss-Ura more efficiently U:G 
mismatches than from U:A base pairs.  
Interestingly, the efficiency of the glycosylases varies with the proliferation capacity 
of the tissue. UNG activity gradually increases with the rapidity of cell division in a particular 
tissue. Surprisingly, we found no SMUG1 activity in the intestine which has higher 
proliferation rate than any other tissues in our sample set. Brain, which is a non-proliferative 
tissue, contains higher amount of SMUG1 activity compared with UNG. Therefore, these 
results postulate that the extent of glycosylase activity varies between organs and that 
SMUG1 is more active in non-proliferative tissues than in proliferating ones. In our 
experiments, we have not examined activities in mitochondria and nuclei separately. UNG is 
known to be present in both nuclei (UNG2) and mitochondria (UNG1), whereas SMUG1 has 
only been found in nuclei. It is possible (but not demonstrated) that in non-proliferating 
tissues rich in mitochondria (e.g. muscle, heart and brain), the UNG-activity we measure 
could be mainly the mitochondrial form, whereas SMUG1 may be a dominant uracil-DNA 
glycosylase in the nuclei. This remains to be investigated.  
Our efforts to examine the content of genomic uracil in different organs did not 
demonstrate clear evidence for a relationship to glycosylase activity. These results should be 
considered preliminary, since we did not have sufficient time to optimize conditions and 
repeat the experiments the sufficient number of times. There is however, a trend that tissues 
from UNG 
-/-
 mice have higher levels of dUrd. 
Lastly, to measure specific glycosylase activity, we have used a particular salt 
condition and four distinct oligonucleotide sequences that do not represent the overall 
physiological pH and the whole genome, respectively. So, in order to estimate the 
heterogeneity of different glycosylase activities, we need to obtain more number of tissues, 
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and further experiment on other oligonucleotide sequences that represent small sets of the 
genome.  
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